VEGFA and ovarian cancer: Considering the tempting hypothesis that higher levels of VEGF downstream bioactivity potentially correlate with increased responses to bevacizumab, we reasoned that it might be important to comprehensively characterize the VDGs in the context of ovarian cancer.